Cyclin-Dependent Kinase Inhibitor p21
"Cyclin-Dependent Kinase Inhibitor p21" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclin-dependent kinase inhibitor that mediates TUMOR SUPPRESSOR PROTEIN P53-dependent CELL CYCLE arrest. p21 interacts with a range of CYCLIN-DEPENDENT KINASES and associates with PROLIFERATING CELL NUCLEAR ANTIGEN and CASPASE 3.
| Descriptor ID |
D050759
|
| MeSH Number(s) |
D12.644.360.225.500 D12.776.157.687.250 D12.776.167.187.500 D12.776.476.225.500 D12.776.624.776.355.500 D12.776.660.720.250
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p21- Cyclin-Dependent Kinase Inhibitor p21
- Cyclin Dependent Kinase Inhibitor p21
- CDKN1 Protein
- Senescent Cell-Derived Inhibitor Protein 1
- Senescent Cell Derived Inhibitor Protein 1
- Cell Cycle Regulator p21
- Cyclin-Dependent Kinase Inhibitor 1A Protein
- Cyclin Dependent Kinase Inhibitor 1A Protein
- Cyclin Kinase Inhibitor p21
- p21 Cyclin Kinase Inhibitor
- CDKN1A Protein
- Cdk-Interacting Protein 1
- Cdk Interacting Protein 1
- Cdk2 Inhibitor Protein
- CDK2-Associated Protein 20 kDa
- CDK2 Associated Protein 20 kDa
- p21 Cell Cycle Regulator
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p21".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p21".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p21" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p21" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 10 | 10 |
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 10 | 10 |
| 1998 | 0 | 22 | 22 |
| 1999 | 0 | 22 | 22 |
| 2000 | 0 | 17 | 17 |
| 2001 | 0 | 16 | 16 |
| 2002 | 0 | 18 | 18 |
| 2003 | 0 | 21 | 21 |
| 2004 | 1 | 24 | 25 |
| 2005 | 2 | 20 | 22 |
| 2006 | 7 | 7 | 14 |
| 2007 | 4 | 8 | 12 |
| 2008 | 3 | 5 | 8 |
| 2009 | 5 | 8 | 13 |
| 2010 | 10 | 13 | 23 |
| 2011 | 5 | 7 | 12 |
| 2012 | 3 | 6 | 9 |
| 2013 | 4 | 4 | 8 |
| 2014 | 2 | 7 | 9 |
| 2015 | 2 | 4 | 6 |
| 2016 | 1 | 5 | 6 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 1 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p21" by people in Profiles.
-
CDK regulators-Cell cycle progression or apoptosis-Scenarios in normal cells and cancerous cells. Adv Protein Chem Struct Biol. 2023; 135:125-177.
-
The REG? inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells. Nat Commun. 2020 08 06; 11(1):3904.
-
TFEB Modulates p21/WAF1/CIP1 during the DNA Damage Response. Cells. 2020 05 10; 9(5).
-
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020 03; 10(3):440-459.
-
Absence of cyclin-dependent kinase inhibitor p27 or p18 increases efficiency of iPSC generation without induction of iPSC genomic instability. Cell Death Dis. 2019 03 20; 10(4):271.
-
Streamlined computational pipeline for genetic background characterization of genetically engineered mice based on next generation sequencing data. BMC Genomics. 2019 Feb 12; 20(1):131.
-
Protein phosphatase 5 and the tumor suppressor p53 down-regulate each other's activities in mice. J Biol Chem. 2018 11 23; 293(47):18218-18229.
-
Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer. FASEB J. 2019 02; 33(2):1644-1657.
-
Cooperative p16 and p21 action protects female astrocytes from transformation. Acta Neuropathol Commun. 2018 02 20; 6(1):12.
-
MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res. 2018 01 01; 78(1):64-74.